BioCentury | Apr 13, 2018
Company News

Novartis to acquire AveXis for $8.7B

...has two other gene therapies in Phase Ib testing: CGF166 to treat hearing loss and CPK850...
...a cDNA carrying the atonal homolog 1 (ATOH1; HATH1) transcription factor delivered via intra-labyrinthine infusion. CPK850...
BioCentury | Apr 9, 2018
Company News

Novartis to acquire AveXis for $8.7B

...has two other gene therapies in Phase Ib testing: CGF166 to treat hearing loss and CPK850...
...a cDNA carrying the atonal homolog 1 (ATOH1; HATH1) transcription factor delivered via intra-labyrinthine infusion. CPK850...
Items per page:
1 - 2 of 2